3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Neoplasm Metastasis
2
Melanoma
2
Esophageal Squamous Cell Carcinoma
2
Advanced Solid Tumour
2
Advanced Solid Tumor
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Simpson-Golabi-Behmel syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Diabetes Mellitus
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumors
1
Advanced Malignancies
1
Adenocarcinoma Of Esophagus
1
Interventions
Oxaliplatin
8
Fluorouracil
8
Nivolumab
7
Leucovorin
7
Paclitaxel
6
Capecitabine
5
Taxes
4
Specimen Handling
4
pembrolizumab
3
Trastuzumab
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Cisplatin
3
zimberelimab
2
zanidatamab
2
Radiotherapy
2
Folfox protocol
2
Carboplatin
2
zolbetuximab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
tislelizumab
1
quemliclustat
1
obeticholic acid
1
futibatinib
1
dehydroftorafur
1
cixutumumab
1
balstilimab
1
Saline Solution
1
Radiofrequency Ablation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
tislelizumab
×
30 days
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled